{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Epidemiology",
      "Immunology",
      "SARS-CoV-2",
      "Vaccine",
      "Virology"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33234420",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "11",
        "Day": "19"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.biologicals.2020.11.003",
      "S1045-1056(20)30137-8"
    ],
    "Journal": {
      "ISSN": "1095-8320",
      "JournalIssue": {
        "Volume": "69",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Biologicals : journal of the International Association of Biological Standardization",
      "ISOAbbreviation": "Biologicals"
    },
    "ArticleTitle": "Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic.",
    "Pagination": {
      "StartPage": "76",
      "EndPage": "82",
      "MedlinePgn": "76-82"
    },
    "Abstract": {
      "AbstractText": [
        "This International Alliance for Biological Standardization COVID-19 webinar was organized to provide an update on the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2, none months after COVID-19 was declared a public health emergency of international concern. It brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address: marc.baay@p-95.com."
          }
        ],
        "LastName": "Baay",
        "ForeName": "Marc",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University Claude Bernard Lyon, VirPath Research Laboratory, Lyon, France. Electronic address: bruno.lina@univ-lyon1.fr."
          }
        ],
        "LastName": "Lina",
        "ForeName": "Bruno",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Global Health, Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France. Electronic address: arnaud.fontanet@pasteur.fr."
          }
        ],
        "LastName": "Fontanet",
        "ForeName": "Arnaud",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Medical Immunology, Universit\u00e9 libre de Bruxelles, Brussels, Belgium. Electronic address: arnaud.marchant@ulb.be."
          }
        ],
        "LastName": "Marchant",
        "ForeName": "Arnaud",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaccine R&D, CEPI, London, United Kingdom. Electronic address: melanie.saville@cepi.net."
          }
        ],
        "LastName": "Saville",
        "ForeName": "Melanie",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: philippe.sabot@iabs.org."
          }
        ],
        "LastName": "Sabot",
        "ForeName": "Philippe",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: joris.vandeputte@iabs.org."
          }
        ],
        "LastName": "Vandeputte",
        "ForeName": "Joris",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: Pieter.neels@vaccine-advice.be."
          }
        ],
        "LastName": "Neels",
        "ForeName": "Pieter",
        "Initials": "P"
      }
    ],
    "GrantList": [
      {
        "Acronym": "WT_",
        "Agency": "Wellcome Trust",
        "Country": "United Kingdom"
      },
      {
        "GrantID": "MR/R005982/1",
        "Acronym": "MRC_",
        "Agency": "Medical Research Council",
        "Country": "United Kingdom"
      }
    ],
    "PublicationTypeList": [
      "Congress"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Biologicals",
    "NlmUniqueID": "9004494",
    "ISSNLinking": "1045-1056"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Neutralizing"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biological Products"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "biosynthesis"
      ],
      "DescriptorName": "Antibodies, Neutralizing"
    },
    {
      "QualifierName": [
        "biosynthesis"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "Biological Products"
    },
    {
      "QualifierName": [
        "epidemiology",
        "etiology",
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "isolation & purification"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "trends"
      ],
      "DescriptorName": "Drug Development"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Europe"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunity, Cellular"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Safety"
    },
    {
      "QualifierName": [],
      "DescriptorName": "World Health Organization"
    }
  ],
  "CoiStatement": "The authors have no competing interests to declare."
}